Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 529 entries
Sorted by: Best Match Show Resources per page
Royal Alexander Brink (1897-1984).

Genetics

Owen RD, Nelson OE.
PMID: 3510941
Genetics. 1986 Jan;112(1):1-10.

No abstract available.

Cite
Owen RD, Nelson OE. Royal Alexander Brink (1897-1984). Genetics. 1986;112(1):1-10
Owen, R. D., & Nelson, O. E. (1986). Royal Alexander Brink (1897-1984). Genetics, 112(1), 1-10.
Owen, R D, and Nelson, O E. "Royal Alexander Brink (1897-1984)." Genetics vol. 112,1 (1986): 1-10.
Owen RD, Nelson OE. Royal Alexander Brink (1897-1984). Genetics. 1986 Jan;112(1):1-10. PMID: 3510941.
Copy Download .nbib Format: NLM
Homozygosity for the V377I mutation in mevalonate kinase causes distinct clinical phenotypes in two sibs with hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS).

RMD open

Messer L, Alsaleh G, Georgel P, Carapito R, Waterham HR, Dali-Youcef N, Bahram S, Sibilia J.
PMID: 26977311
RMD Open. 2016 Mar 07;2(1):e000196. doi: 10.1136/rmdopen-2015-000196. eCollection 2016.

OBJECTIVE: Mevalonate kinase (MVK) deficiency is a rare autosomal recessive auto-inflammatory disorder characterised by recurring episodes of fever associated with multiple non-specific inflammatory symptoms and caused by mutations in the MVK gene. The phenotypic spectrum is wide and depends...

Cite
Messer L, Alsaleh G, Georgel P, et al. Homozygosity for the V377I mutation in mevalonate kinase causes distinct clinical phenotypes in two sibs with hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS). RMD Open. 2016;2(1):e000196doi: 10.1136/rmdopen-2015-000196.
Messer, L., Alsaleh, G., Georgel, P., Carapito, R., Waterham, H. R., Dali-Youcef, N., Bahram, S., & Sibilia, J. (2016). Homozygosity for the V377I mutation in mevalonate kinase causes distinct clinical phenotypes in two sibs with hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS). RMD open, 2(1), e000196. https://doi.org/10.1136/rmdopen-2015-000196
Messer, Laurent, et al. "Homozygosity for the V377I mutation in mevalonate kinase causes distinct clinical phenotypes in two sibs with hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS)." RMD open vol. 2,1 (2016): e000196. doi: https://doi.org/10.1136/rmdopen-2015-000196
Messer L, Alsaleh G, Georgel P, Carapito R, Waterham HR, Dali-Youcef N, Bahram S, Sibilia J. Homozygosity for the V377I mutation in mevalonate kinase causes distinct clinical phenotypes in two sibs with hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS). RMD Open. 2016 Mar 07;2(1):e000196. doi: 10.1136/rmdopen-2015-000196. eCollection 2016. PMID: 26977311; PMCID: PMC4785531.
Copy Download .nbib Format: NLM
Correction.

RMD open

[No authors listed]
PMID: 26629365
RMD Open. 2015 Oct 28;1(1):e000146corr1. doi: 10.1136/rmdopen-2015-000146corr1. eCollection 2015.

[This corrects the article DOI: 10.1136/rmdopen-2015-000146.].

Cite
Correction. RMD Open. 2015;1(1):e000146corr1doi: 10.1136/rmdopen-2015-000146corr1.
(2015). Correction. RMD open, 1(1), e000146corr1. https://doi.org/10.1136/rmdopen-2015-000146corr1
"Correction." RMD open vol. 1,1 (2015): e000146corr1. doi: https://doi.org/10.1136/rmdopen-2015-000146corr1
Correction. RMD Open. 2015 Oct 28;1(1):e000146corr1. doi: 10.1136/rmdopen-2015-000146corr1. eCollection 2015. PMID: 26629365; PMCID: PMC4654162.
Copy Download .nbib Format: NLM
Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures.

RMD open

Kremer JM, Lawrence DA, Hamilton R, McInnes IB.
PMID: 27335660
RMD Open. 2016 Jun 09;2(1):e000287. doi: 10.1136/rmdopen-2016-000287. eCollection 2016.

OBJECTIVE: To describe changes in immune parameters observed during long-term methotrexate (MTX) therapy in patients with active rheumatoid arthritis (RA) and explore correlations with simultaneously measured MTX pharmacokinetic (PKC) parameters.DESIGN: Prospective, open-label, long-term mechanism of action study.SETTING: University clinic.METHODS:...

Cite
Kremer JM, Lawrence DA, Hamilton R, et al. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open. 2016;2(1):e000287doi: 10.1136/rmdopen-2016-000287.
Kremer, J. M., Lawrence, D. A., Hamilton, R., & McInnes, I. B. (2016). Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD open, 2(1), e000287. https://doi.org/10.1136/rmdopen-2016-000287
Kremer, Joel M, et al. "Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures." RMD open vol. 2,1 (2016): e000287. doi: https://doi.org/10.1136/rmdopen-2016-000287
Kremer JM, Lawrence DA, Hamilton R, McInnes IB. Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open. 2016 Jun 09;2(1):e000287. doi: 10.1136/rmdopen-2016-000287. eCollection 2016. PMID: 27335660; PMCID: PMC4913203.
Copy Download .nbib Format: NLM
Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology.

RMD open

Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scirè CA.
PMID: 29071118
RMD Open. 2017 Sep 28;3(2):e000523. doi: 10.1136/rmdopen-2017-000523. eCollection 2017.

OBJECTIVES: The purpose of this study was to evaluate the risk of developing rheumatoid arthritis (RA) in a population of patients with breast cancer treated with aromatase inhibitors (AIs) compared with tamoxifen.METHODS: Data were collected from the administrative healthcare...

Cite
Caprioli M, Carrara G, Sakellariou G, et al. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017;3(2):e000523doi: 10.1136/rmdopen-2017-000523.
Caprioli, M., Carrara, G., Sakellariou, G., Silvagni, E., & Scirè, C. A. (2017). Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD open, 3(2), e000523. https://doi.org/10.1136/rmdopen-2017-000523
Caprioli, Marta, et al. "Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology." RMD open vol. 3,2 (2017): e000523. doi: https://doi.org/10.1136/rmdopen-2017-000523
Caprioli M, Carrara G, Sakellariou G, Silvagni E, Scirè CA. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017 Sep 28;3(2):e000523. doi: 10.1136/rmdopen-2017-000523. eCollection 2017. PMID: 29071118; PMCID: PMC5640089.
Copy Download .nbib Format: NLM
Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.

RMD open

Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A.
PMID: 29018564
RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017.

OBJECTIVE: To evaluate the achievement of comprehensive disease control (CDC) following 1 year of treatment with adalimumab+methotrexate versus methotrexate alone and whether early achievement of remission (at week 24 or 26) is associated with CDC at week 52 in...

Cite
Keystone EC, Breedveld FC, van der Heijde D, et al. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017;3(2):e000445doi: 10.1136/rmdopen-2017-000445.
Keystone, E. C., Breedveld, F. C., van der Heijde, D., van Vollenhoven, R. F., Emery, P., Smolen, J. S., Sainsbury, I., Florentinus, S., Kupper, H., Chen, K., & Kavanaugh, A. (2017). Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD open, 3(2), e000445. https://doi.org/10.1136/rmdopen-2017-000445
Keystone, Edward C, et al. "Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone." RMD open vol. 3,2 (2017): e000445. doi: https://doi.org/10.1136/rmdopen-2017-000445
Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017. PMID: 29018564; PMCID: PMC5623327.
Copy Download .nbib Format: NLM
Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study.

RMD open

Marques A, Lucas R, Simões E, Verstappen SMM, Jacobs JWG, da Silva JAP.
PMID: 29018567
RMD Open. 2017 Sep 26;3(2):e000509. doi: 10.1136/rmdopen-2017-000509. eCollection 2017.

OBJECTIVE: Evaluate the performance of FRAX®, with and without bone mineral densitometry (BMD), in predicting the occurrence of fragility fractures over 10 years.METHODS: Participants aged ≥40 years at baseline, with a complete set of data and a minimum of...

Cite
Marques A, Lucas R, Simões E, et al. Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. RMD Open. 2017;3(2):e000509doi: 10.1136/rmdopen-2017-000509.
Marques, A., Lucas, R., Simões, E., Verstappen, S. M. M., Jacobs, J. W. G., & da Silva, J. A. P. (2017). Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. RMD open, 3(2), e000509. https://doi.org/10.1136/rmdopen-2017-000509
Marques, Andréa, et al. "Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study." RMD open vol. 3,2 (2017): e000509. doi: https://doi.org/10.1136/rmdopen-2017-000509
Marques A, Lucas R, Simões E, Verstappen SMM, Jacobs JWG, da Silva JAP. Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. RMD Open. 2017 Sep 26;3(2):e000509. doi: 10.1136/rmdopen-2017-000509. eCollection 2017. PMID: 29018567; PMCID: PMC5623321.
Copy Download .nbib Format: NLM
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis.

RMD open

Fleischmann R, Alam J, Arora V, Bradley J, Schlichting DE, Muram D, Smolen JS.
PMID: 29071120
RMD Open. 2017 Oct 10;3(2):e000546. doi: 10.1136/rmdopen-2017-000546. eCollection 2017.

No abstract available.

Cite
Fleischmann R, Alam J, Arora V, et al. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 2017;3(2):e000546doi: 10.1136/rmdopen-2017-000546.
Fleischmann, R., Alam, J., Arora, V., Bradley, J., Schlichting, D. E., Muram, D., & Smolen, J. S. (2017). Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD open, 3(2), e000546. https://doi.org/10.1136/rmdopen-2017-000546
Fleischmann, Roy, et al. "Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis." RMD open vol. 3,2 (2017): e000546. doi: https://doi.org/10.1136/rmdopen-2017-000546
Fleischmann R, Alam J, Arora V, Bradley J, Schlichting DE, Muram D, Smolen JS. Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis. RMD Open. 2017 Oct 10;3(2):e000546. doi: 10.1136/rmdopen-2017-000546. eCollection 2017. PMID: 29071120; PMCID: PMC5640108.
Copy Download .nbib Format: NLM
Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study.

RMD open

Putrik P, Ramiro S, Chorus AM, Keszei AP, Boonen A.
PMID: 26535136
RMD Open. 2015 May 21;1(1):e000045. doi: 10.1136/rmdopen-2014-000045. eCollection 2015.

OBJECTIVES: To explore the impact of socioeconomic factors on physical and mental health of patients with musculoskeletal disorders (MSKDs) and compare it across patients with other disorders.METHODS: A representative sample of the Dutch population (n=8904) completed a survey on...

Cite
Putrik P, Ramiro S, Chorus AM, et al. Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study. RMD Open. 2015;1(1):e000045doi: 10.1136/rmdopen-2014-000045.
Putrik, P., Ramiro, S., Chorus, A. M., Keszei, A. P., & Boonen, A. (2015). Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study. RMD open, 1(1), e000045. https://doi.org/10.1136/rmdopen-2014-000045
Putrik, P, et al. "Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study." RMD open vol. 1,1 (2015): e000045. doi: https://doi.org/10.1136/rmdopen-2014-000045
Putrik P, Ramiro S, Chorus AM, Keszei AP, Boonen A. Socioeconomic inequities in perceived health among patients with musculoskeletal disorders compared with other chronic disorders: results from a cross-sectional Dutch study. RMD Open. 2015 May 21;1(1):e000045. doi: 10.1136/rmdopen-2014-000045. eCollection 2015. PMID: 26535136; PMCID: PMC4612684.
Copy Download .nbib Format: NLM
Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis.

RMD open

Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE.
PMID: 26535138
RMD Open. 2015 May 21;1(1):e000080. doi: 10.1136/rmdopen-2015-000080. eCollection 2015.

OBJECTIVE: To assess the effects of treatment with antitumour necrosis factor (TNF) agents, methotrexate, or other non-biological disease-modifying antirheumatic drugs (DMARDs) on cardiovascular event risks among patients with rheumatoid arthritis (RA).METHODS: We conducted a retrospective study using data from...

Cite
Nurmohamed M, Bao Y, Signorovitch J, et al. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015;1(1):e000080doi: 10.1136/rmdopen-2015-000080.
Nurmohamed, M., Bao, Y., Signorovitch, J., Trahey, A., Mulani, P., & Furst, D. E. (2015). Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD open, 1(1), e000080. https://doi.org/10.1136/rmdopen-2015-000080
Nurmohamed, Michael, et al. "Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis." RMD open vol. 1,1 (2015): e000080. doi: https://doi.org/10.1136/rmdopen-2015-000080
Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015 May 21;1(1):e000080. doi: 10.1136/rmdopen-2015-000080. eCollection 2015. PMID: 26535138; PMCID: PMC4612693.
Copy Download .nbib Format: NLM
Biosimilars: what do patients need to consider?.

RMD open

Skingle D.
PMID: 26535149
RMD Open. 2015 Sep 16;1(1):e000141. doi: 10.1136/rmdopen-2015-000141. eCollection 2015.

A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to...

Cite
Skingle D. Biosimilars: what do patients need to consider?. RMD Open. 2015;1(1):e000141doi: 10.1136/rmdopen-2015-000141.
Skingle, D. (2015). Biosimilars: what do patients need to consider?. RMD open, 1(1), e000141. https://doi.org/10.1136/rmdopen-2015-000141
Skingle, Diana. "Biosimilars: what do patients need to consider?." RMD open vol. 1,1 (2015): e000141. doi: https://doi.org/10.1136/rmdopen-2015-000141
Skingle D. Biosimilars: what do patients need to consider?. RMD Open. 2015 Sep 16;1(1):e000141. doi: 10.1136/rmdopen-2015-000141. eCollection 2015. PMID: 26535149; PMCID: PMC4623364.
Copy Download .nbib Format: NLM
Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry.

RMD open

Manders SH, van de Laar MA, Rongen-van Dartel SA, Bos R, Visser H, Brus HL, Jansen T, Vonkeman HE, van Riel PL, Kievit W.
PMID: 26535151
RMD Open. 2015 Oct 08;1(1):e000147. doi: 10.1136/rmdopen-2015-000147. eCollection 2015.

OBJECTIVES: To study the number of patients that taper or discontinue concomitant methotrexate (MTX) in daily practice in patients with rheumatoid arthritis (RA) treated with tumour necrosis factor inhibitor (TNFi) and to analyse the effects of that adaption on...

Cite
Manders SH, van de Laar MA, Rongen-van Dartel SA, et al. Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. RMD Open. 2015;1(1):e000147doi: 10.1136/rmdopen-2015-000147.
Manders, S. H., van de Laar, M. A., Rongen-van Dartel, S. A., Bos, R., Visser, H., Brus, H. L., Jansen, T., Vonkeman, H. E., van Riel, P. L., & Kievit, W. (2015). Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. RMD open, 1(1), e000147. https://doi.org/10.1136/rmdopen-2015-000147
Manders, Sofie H M, et al. "Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry." RMD open vol. 1,1 (2015): e000147. doi: https://doi.org/10.1136/rmdopen-2015-000147
Manders SH, van de Laar MA, Rongen-van Dartel SA, Bos R, Visser H, Brus HL, Jansen T, Vonkeman HE, van Riel PL, Kievit W. Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry. RMD Open. 2015 Oct 08;1(1):e000147. doi: 10.1136/rmdopen-2015-000147. eCollection 2015. PMID: 26535151; PMCID: PMC4623370.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 529 entries